COATS LONNEL — SEC insider filings

SEC reporting owner CIK 1612528. 29 insider filings on record with FilingPulse; latest filed 2026-10-20.

Transaction summary — filings shown

Covers all 29 filings on record, filed 2021-02-16 to 2026-10-20. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Blueprint Medicines Corp (BPMC)Director7—4 legs · 19,824 sh · $1,869,65823
LEXICON PHARMACEUTICALS, INC. (LXRX)Chief Executive Officer, Director136 legs · 170,000 sh · $265,639—38
Verve Therapeutics, Inc. (VERV)Director5——6
Mineralys Therapeutics, Inc. (MLYS)Director2——2
Relay Therapeutics, Inc. (RLAY)Director2——2

Insider filings — COATS LONNEL

FiledFormIssuerReported transactionsSource
2026-10-203Mineralys Therapeutics, Inc. (MLYS)Holdings only — no transactions reportedEDGAR
2026-10-204Mineralys Therapeutics, Inc. (MLYS)Grant/award (A): 12,400 @ $0 · Grant/award (A): 16,600 (derivative) @ $0EDGAR
2026-06-104Relay Therapeutics, Inc. (RLAY)Grant/award (A): 32,947 (derivative) @ $0EDGAR
2025-11-064Relay Therapeutics, Inc. (RLAY)Grant/award (A): 207,931 (derivative) @ $0EDGAR
2025-07-284Verve Therapeutics, Inc. (VERV)Disposition to issuer (D): 136,139 (derivative) · Disposition to issuer (D): 42,200 (derivative)EDGAR
2025-07-214Blueprint Medicines Corp (BPMC)Disposition to issuer (D): 6,144 · Disposition to issuer (D): 11,818 (derivative) · Disposition to issuer (D): 10,909 (derivative) · Disposition to issuer (D): 10,909 (derivative) · Disposition to issuer (D): 4,875 (derivative) · Disposition to issuer (D): 3,188 (derivative) · +4 moreEDGAR
2025-06-244Blueprint Medicines Corp (BPMC)Grant/award (A): 3,902 @ $12,812EDGAR
2025-06-064Verve Therapeutics, Inc. (VERV)Grant/award (A): 42,200 (derivative) @ $0EDGAR
2024-11-224Blueprint Medicines Corp (BPMC)Option exercise (M): 7,500 @ $69.79 · Option exercise (M): 1,312 @ $76.24 · Sale (S): 4,500 @ $93.15 · Sale (S): 5,287 @ $94.24 · Sale (S): 213 @ $94.99 · Sale (S): 9,824 @ $94.87 · +2 moreEDGAR
2024-06-284Verve Therapeutics, Inc. (VERV)Grant/award (A): 136,139 (derivative) @ $0EDGAR
2024-06-144Blueprint Medicines Corp (BPMC)Grant/award (A): 2,242 @ $0 · Grant/award (A): 4,570 (derivative) @ $0EDGAR
2024-02-294LEXICON PHARMACEUTICALS, INC. (LXRX)Option exercise (M): 33,333 · Option exercise (M): 91,364 · Option exercise (M): 120,383 · Tax withholding (F): 61,371 @ $2.62 · Option exercise (M): 33,333 (derivative) · Option exercise (M): 91,364 (derivative) · +1 moreEDGAR
2024-02-124LEXICON PHARMACEUTICALS, INC. (LXRX)Grant/award (A): 770,420 (derivative) @ $0 · Grant/award (A): 770,420 (derivative) @ $0EDGAR
2023-11-174LEXICON PHARMACEUTICALS, INC. (LXRX)Purchase (P): 90,000 @ $1.05EDGAR
2023-11-134LEXICON PHARMACEUTICALS, INC. (LXRX)Purchase (P): 10,000 @ $1.01EDGAR
2023-06-294LEXICON PHARMACEUTICALS, INC. (LXRX)Purchase (P): 10,000 @ $2.16EDGAR
2023-06-264LEXICON PHARMACEUTICALS, INC. (LXRX)Purchase (P): 10,000 @ $2.50 · Purchase (P): 10,000 @ $2.18EDGAR
2023-06-234Blueprint Medicines Corp (BPMC)Grant/award (A): 2,600 @ $0 · Grant/award (A) @ $0EDGAR
2023-06-224LEXICON PHARMACEUTICALS, INC. (LXRX)Purchase (P): 40,000 @ $2.31EDGAR
2023-06-204Verve Therapeutics, Inc. (VERV)Grant/award (A): 26,642 (derivative) @ $0EDGAR
2023-03-014LEXICON PHARMACEUTICALS, INC. (LXRX)Option exercise (M): 84,630 · Option exercise (M): 33,334 · Option exercise (M): 91,363 · Tax withholding (F): 50,971 @ $2.17 · Option exercise (M): 84,630 (derivative) · Option exercise (M): 33,334 (derivative) · +1 moreEDGAR
2023-02-134LEXICON PHARMACEUTICALS, INC. (LXRX)Grant/award (A): 361,150 (derivative) @ $0 · Grant/award (A): 1,083,440 (derivative) @ $0EDGAR
2022-08-094Verve Therapeutics, Inc. (VERV)Grant/award (A): 31,000 (derivative) @ $0EDGAR
2022-06-304Blueprint Medicines Corp (BPMC)Grant/award (A): 2,600 @ $0 · Grant/award (A): 5,300 (derivative) @ $0EDGAR
2022-02-284LEXICON PHARMACEUTICALS, INC. (LXRX)Option exercise (M): 79,380 · Option exercise (M): 84,630 · Option exercise (M): 33,333 · Tax withholding (F): 48,053 @ $2.85 · Option exercise (M): 79,380 (derivative) · Option exercise (M): 84,630 (derivative) · +1 moreEDGAR
2022-02-144LEXICON PHARMACEUTICALS, INC. (LXRX)Grant/award (A): 822,280 (derivative) @ $0 · Grant/award (A): 274,090 (derivative) @ $0EDGAR
2021-06-044Blueprint Medicines Corp (BPMC)Grant/award (A): 2,250 @ $0 · Grant/award (A): 4,500 (derivative) @ $0EDGAR
2021-03-024LEXICON PHARMACEUTICALS, INC. (LXRX)Option exercise (M): 5,362 · Option exercise (M): 23,513 · Option exercise (M): 79,380 · Option exercise (M): 84,630 · Tax withholding (F): 55,038 @ $7.19 · Option exercise (M): 5,362 (derivative) · +3 moreEDGAR
2021-02-164LEXICON PHARMACEUTICALS, INC. (LXRX)Grant/award (A): 100,000 (derivative) @ $0 · Grant/award (A): 300,000 (derivative) @ $0EDGAR

FilingPulse's Form 4 archive currently extends back to 2021-02-16 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1612528 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs